
The Anglo-Swedish multinational AstraZeneca is moving towards becoming a major healthcare provider in China as part of an effort to …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

